Plain-English translation of NCT05764538 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a 24-week study testing a medication called to see if it can help improve thinking, memory, mood, and overall quality of life in people dealing with brain fog and cognitive problems after COVID-19. All participants will receive the medication for the full 6 months. The researchers believe this treatment may help restore mental clarity and improve daily functioning in long COVID patients.
Many people who have recovered from COVID-19 continue to experience persistent brain fog, trouble concentrating, and memory problems—sometimes for months or even longer. This trial exists to see whether this new medication can help ease these frustrating cognitive symptoms when other treatments haven't worked well enough.
You likely qualify if…
You likely don't qualify if…
You would take the medication daily for 24 weeks (6 months). During that time, you would visit the clinic for check-ups and assessments at weeks 0, 8, 16, and 24—so four visits total spread across the 6-month period. At each visit, the researchers will test your cognitive function, mood, and overall quality of life to see if the treatment is helping. The study is open-label, meaning you and your doctors will know you're receiving the medication.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Taiwan
Phase
Testing effectiveness
Sponsor
Chang Gung Memorial Hospital
Enrollment target
~40 participants
Started
February 2023
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in March 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.